ÌÇÐÄvlog

Object moved to here.

Values and Preferences of Patients and Caregivers Regarding Treatment of Atopic Dermatitis (Eczema): A Systematic Review | Atopic Dermatitis | JAMA Dermatology | ÌÇÐÄvlog

ÌÇÐÄvlog

[Skip to Navigation]
Sign In
1.
Boguniewicz ÌýM, Fonacier ÌýL, Guttman-Yassky ÌýE, Ong ÌýPY, Silverberg ÌýJ, Farrar ÌýJR. ÌýAtopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape.Ìý ÌýAnn Allergy Asthma Immunol. 2018;120(1):10-22.e2. doi:
2.
Bakaa ÌýL, Pernica ÌýJM, Couban ÌýRJ, Ìýet al. ÌýBleach baths for atopic dermatitis: a systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE.Ìý ÌýAnn Allergy Asthma Immunol. 2022;128(6):660-668.e9. doi:
3.
Oykhman ÌýP, Dookie ÌýJ, Al-Rammahy ÌýH, Ìýet al. ÌýDietary elimination for the treatment of atopic dermatitis: a systematic review and meta-analysis.Ìý ÌýJ Allergy Clin Immunol Pract. 2022;10(10):2657-2666.e8. doi:
4.
Chu ÌýDK, Golden ÌýDBK, Guyatt ÌýGH. ÌýTranslating evidence to optimize patient care using GRADE.Ìý ÌýJ Allergy Clin Immunol Pract. 2021;9(12):4221-4230. doi:
5.
Schneider ÌýL, Tilles ÌýS, Lio ÌýP, Ìýet al. ÌýAtopic dermatitis: a practice parameter update 2012.Ìý ÌýJ Allergy Clin Immunol. 2013;131(2):295-9.e1, 27. doi:
6.
Agarwal ÌýA, Chen ÌýL, Capozza ÌýK, Ìýet al. ÌýTrustworthy patient-centered guidelines: insights from atopic dermatitis and a proposal for the future.Ìý ÌýJ Allergy Clin Immunol Pract. 2022;10(11):2875-2877. doi:
7.
Thomas ÌýJ, Harden ÌýA. ÌýMethods for the thematic synthesis of qualitative research in systematic reviews.Ìý ÌýBMC Med Res Methodol. 2008;8:45. doi:
8.
Heen ÌýAF, Lytvyn ÌýL, Shapiro ÌýM, Ìýet al. ÌýPatient values and preferences on valve replacement for aortic stenosis: a systematic review.Ìý Ìý±á±ð²¹°ù³Ù. 2021;107(16):1289-1295. doi:
9.
Zeng ÌýL, Lytvyn ÌýL, Wang ÌýX, Ìýet al. ÌýValues and preferences towards medical cannabis among people living with chronic pain: a mixed-methods systematic review.Ìý Ìýµþ²Ñ´³ Open. 2021;11(9):e050831. doi:
10.
Critical Appraisal Skills Programme. CASP qualitative studies checklist. Accessed December 13, 2022.
11.
Lewin ÌýS, Bohren ÌýM, Rashidian ÌýA, Ìýet al. ÌýApplying GRADE-CERQual to qualitative evidence synthesis findings-paper 2: how to make an overall CERQual assessment of confidence and create a Summary of Qualitative Findings table.Ìý ÌýImplement Sci. 2018;13(suppl 1):10. doi:
12.
de Wijs ÌýLEM, van Egmond ÌýS, Devillers ÌýACA, Nijsten ÌýT, Hijnen ÌýD, Lugtenberg ÌýM. ÌýNeeds and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study.Ìý ÌýArch Dermatol Res. 2022;1-9. doi:
13.
Clement ÌýC, Ridd ÌýMJ, Roberts ÌýK, Ìýet al. ÌýParents and GPs’ understandings and beliefs about food allergy testing in children with eczema: qualitative interview study within the Trial of Eczema allergy Screening Tests (TEST) feasibility trial.Ìý Ìýµþ²Ñ´³ Open. 2020;10(11):e041229. doi:
14.
Ameen ÌýM, Meller ÌýS, Pinter ÌýA, Shear ÌýNH, Soria ÌýA; (the BADEL Study Group). ÌýPerception and experience of biologic therapy in atopic dermatitis: a qualitative focus group study of physicians and patients in Europe and Canada.Ìý ÌýDermatol Ther (Heidelb). 2021;11(6):2159-2177. doi:
15.
Aubert-Wastiaux ÌýH, Moret ÌýL, Le Rhun ÌýA, Ìýet al. ÌýTopical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency.Ìý ÌýBr J Dermatol. 2011;165(4):808-814. doi:
16.
Bazen ÌýA, Sevagamoorthy ÌýA, Barg ÌýFK, Takeshita ÌýJ. Ìý417 Adherence to topical therapy for atopic dermatitis: barriers and facilitators.Ìý ÌýJ Invest Dermatol. 2020;140(7):S54. doi:
17.
Boeri ÌýM, Sutphin ÌýJ, Hauber ÌýB, Cappelleri ÌýJC, Romero ÌýW, Di Bonaventura ÌýM. ÌýQuantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment.Ìý ÌýJ Dermatolog Treat. 2022;33(3):1449-1458. doi:
18.
Burkhart ÌýCN, Burkhart ÌýCG. ÌýPilot study of patient satisfaction with nonfluorinated topical steroids compared with a topical immunomodulator in atopiform dermatitis.Ìý ÌýInt J Dermatol. 2004;43(3):215-219. doi:
19.
Cadmus ÌýSD, Sebastian ÌýKR, Warren ÌýD, Ìýet al. ÌýEfficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: a randomized split-body control study.Ìý ÌýPediatr Dermatol. 2019;36(4):437-441. doi:
20.
Capozza ÌýK, Schwartz ÌýA. ÌýDoes it work and is it safe: parents’ perspectives on adherence to medication for atopic dermatitis.Ìý ÌýPediatr Dermatol. 2020;37(1):58-61. doi:
21.
Charman ÌýCR, Morris ÌýAD, Williams ÌýHC. ÌýTopical corticosteroid phobia in patients with atopic eczema.Ìý ÌýBr J Dermatol. 2000;142(5):931-936. doi:
22.
Djokic-Gallagher ÌýJ, Rosher ÌýP, Oliveira ÌýG, Walker ÌýJ. ÌýA double-blind, randomised study comparing the skin hydration and acceptability of two emollient products in atopic eczema patients with dry skin.Ìý ÌýDermatol Ther (Heidelb). 2017;7(3):397-406. doi:
23.
Draelos ÌýZD. ÌýA clinical evaluation of the comparable efficacy of hyaluronic acid-based foam and ceramide-containing emulsion cream in the treatment of mild-to-moderate atopic dermatitis.Ìý ÌýJ Cosmet Dermatol. 2011;10(3):185-188. doi:
24.
Ervin ÌýC, Crawford ÌýR, Evans ÌýE, Ìýet al. ÌýPatient and caregiver preferences on treatment attributes for atopic dermatitis.Ìý ÌýJ Dermatolog Treat. 2022;33(4):2225-2233. doi:
25.
Fenerty ÌýSD, O’Neill ÌýJL, Gustafson ÌýCJ, Feldman ÌýSR. ÌýMaternal adherence factors in the treatment of pediatric atopic dermatitis.Ìý ÌýJAMA Dermatol. 2013;149(2):229-231. doi:
26.
Fukaya ÌýM. ÌýWhy do patients with atopic dermatitis refuse to apply topical corticosteroids?Ìý Ìý¶Ù±ð°ù³¾²¹³Ù´Ç±ô´Ç²µ²â. 2000;201(3):242-245. doi:
27.
Gerner ÌýT, Haugaard ÌýJH, Vestergaard ÌýC, Ìýet al. ÌýHealthcare utilization in Danish children with atopic dermatitis and parental topical corticosteroid phobia.Ìý ÌýPediatr Allergy Immunol. 2021;32(2):331-341. doi:
28.
Ghio ÌýD, Muller ÌýI, Greenwell ÌýK, Ìýet al. Ìý‘It’s like the bad guy in a movie who just doesn’t die:’ a qualitative exploration of young people’s adaptation to eczema and implications for self-care.Ìý ÌýBr J Dermatol. 2020;182(1):112-118. doi:
29.
Gollnick ÌýH, Luger ÌýT, Freytag ÌýS, Bräutigam ÌýM; STABIEL study group. ÌýStabiEL: stabilization of skin condition with Elidel—a patients’ satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid.Ìý ÌýJ Eur Acad Dermatol Venereol. 2008;22(11):1319-1325. doi:
30.
Gore ÌýC, Johnson ÌýRJ, Caress ÌýAL, Woodcock ÌýA, Custovic ÌýA. ÌýThe information needs and preferred roles in treatment decision-making of parents caring for infants with atopic dermatitis: a qualitative study.Ìý Ìý´¡±ô±ô±ð°ù²µ²â. 2005;60(7):938-943. doi:
31.
Greenwell ÌýK, Ghio ÌýD, Muller ÌýI, Ìýet al. ÌýTaking charge of eczema self-management: a qualitative interview study with young people with eczema.Ìý Ìýµþ²Ñ´³ Open. 2021;11(1):e044005. doi:
32.
Hon ÌýKLE, Kam ÌýWYC, Leung ÌýTF, Ìýet al. ÌýSteroid fears in children with eczema.Ìý ÌýActa Paediatr. 2006;95(11):1451-1455. doi:
33.
Hon ÌýKLE, Wang ÌýSS, Pong ÌýNH, Leung ÌýTF. ÌýThe ideal moisturizer: a survey of parental expectations and practice in childhood-onset eczema.Ìý ÌýJ Dermatolog Treat. 2013;24(1):7-12. doi:
34.
Howells ÌýLM, Chalmers ÌýJR, Cowdell ÌýF, Ratib ÌýS, Santer ÌýM, Thomas ÌýKS. Ìý‘When it goes back to my normal I suppose’: a qualitative study using online focus groups to explore perceptions of ‘control’ among people with eczema and parents of children with eczema in the UK.Ìý Ìýµþ²Ñ´³ Open. 2017;7(11):e017731. doi:
35.
Howells ÌýL, Thomas ÌýKS, Sears ÌýAV, Ìýet al; Long-term control of eczema working group for the HOME initiative. ÌýDefining and measuring ‘eczema control’: an international qualitative study to explore the views of those living with and treating atopic eczema.Ìý ÌýJ Eur Acad Dermatol Venereol. 2019;33(6):1124-1132. doi:
36.
Joergensen ÌýKM, Jemec ÌýGBE. ÌýUse of moisturizers among Danish atopic dermatitis patients—which perceived product characteristics associate with long-term adherence?Ìý ÌýJ Dermatolog Treat. 2018;29(2):116-122. doi:
37.
Johnson ÌýMC, Heron ÌýCE, Feldman ÌýSR. ÌýCaregiver preferences for the treatment of childhood atopic dermatitis.Ìý ÌýJ Cutan Med Surg. 2021;25(3):336-338. doi:
38.
Johnston ÌýGA, Bilbao ÌýRM, Graham-Brown ÌýRA. ÌýThe use of complementary medicine in children with atopic dermatitis in secondary care in Leicester.Ìý ÌýBr J Dermatol. 2003;149(3):566-571. doi:
39.
Jung ÌýHJ, Bae ÌýJY, Kim ÌýJE, Ìýet al. ÌýSurvey of disease awareness, treatment behavior and treatment satisfaction in patients with atopic dermatitis in Korea: a multicenter study.Ìý ÌýJ Dermatol. 2018;45(10):1172-1180. doi:
40.
Kamei ÌýK, Hirose ÌýT, Yoshii ÌýN, Tanaka ÌýA. ÌýBurden of illness, medication adherence, and unmet medical needs in Japanese patients with atopic dermatitis: a retrospective analysis of a cross-sectional questionnaire survey.Ìý ÌýJ Dermatol. 2021;48(10):1491-1498. doi:
41.
Kosse ÌýRC, Bouvy ÌýML, Daanen ÌýM, de Vries ÌýTW, Koster ÌýES. ÌýAdolescents’ perspectives on atopic dermatitis treatment-experiences, preferences, and beliefs.Ìý ÌýJAMA Dermatol. 2018;154(7):824-827. doi:
42.
Koster ÌýES, Philbert ÌýD, Wagelaar ÌýKR, Galle ÌýS, Bouvy ÌýML. ÌýOptimizing pharmaceutical care for pediatric patients with dermatitis: perspectives of parents and pharmacy staff.Ìý ÌýInt J Clin Pharm. 2019;41(3):711-718. doi:
43.
Kunkiel ÌýK, NatkaÅ„ska ÌýA, NÄ™dzi ÌýM, Zawadzka-Krajewska ÌýA, Feleszko ÌýW. ÌýPatients’ preferences of leave-on emollients: a survey on patients with atopic dermatitis.Ìý ÌýJ Dermatolog Treat. 2022;33(2):1143-1145. doi:
44.
Kurtti ÌýA, Jagdeo ÌýJ. ÌýAnalysis of Reddit reveals atopic dermatitis patient questions.Ìý ÌýJ Drugs Dermatol. 2021;20(6):653-658. doi:
45.
Lee ÌýJY, Her ÌýY, Kim ÌýCW, Kim ÌýSS. ÌýTopical corticosteroid phobia among parents of children with atopic eczema in Korea.Ìý ÌýAnn Dermatol. 2015;27(5):499-506. doi:
46.
Rhun ÌýAL, Wastiaux ÌýHA, Moret ÌýL, Ìýet al. ÌýFears regarding the use of topical corticosteroids in atopic dermatitis: looking at the coping strategies and the role of health care providers: a qualitative study.Ìý ÌýEduc Ther Patient/ÌýTher Patient Educ. 2015;7(2):20102. doi:
47.
Li ÌýY, Han ÌýT, Li ÌýW, Li ÌýY, Guo ÌýX, Zheng ÌýL. ÌýAwareness of and phobias about topical corticosteroids in parents of infants with eczema in Hangzhou, China.Ìý ÌýPediatr Dermatol. 2018;35(4):463-467. doi:
48.
Lundin ÌýS, Jonsson ÌýM, Wahlgren ÌýC, Johansson ÌýE, Bergstrom ÌýA, Kull ÌýI. Ìý“You try to take as little as possibleâ€â€”a qualitative study of young adults with eczema recruited from the population-based birth cohort (BAMSE).Ìý Ìý´¡±ô±ô±ð°ù²µ²â. 2019;74(S106):130-331.
49.
Lundin ÌýS, Jonsson ÌýM, Wahlgren ÌýCF, Johansson ÌýE, Bergstrom ÌýA, Kull ÌýI. ÌýYoung adults’ perceptions of living with atopic dermatitis in relation to the concept of self-management: a qualitative study.Ìý Ìýµþ²Ñ´³ Open. 2021;11(6):e044777. doi:
50.
Maghen ÌýP, Unrue ÌýEL, Oussedik ÌýE, Cline ÌýA, Cardwell ÌýLA, Feldman ÌýSR. ÌýRegardless of how risks are framed, patients seem hesitant to use topical steroids for atopic dermatitis.Ìý ÌýBr J Dermatol. 2019;181(4):842-844. doi:
51.
McAlister ÌýRO, Tofte ÌýSJ, Doyle ÌýJJ, Jackson ÌýA, Hanifin ÌýJM. ÌýPatient and physician perspectives vary on atopic dermatitis.Ìý Ìý°ä³Ü³Ù¾±²õ. 2002;69(6):461-466.
52.
Noerreslet ÌýM, Jemec ÌýGBE, Traulsen ÌýJM. ÌýInvoluntary autonomy: patients’ perceptions of physicians, conventional medicines and risks in the management of atopic dermatitis.Ìý ÌýSoc Sci Med. 2009;69(9):1409-1415. doi:
53.
Nørreslet ÌýM, Bissell ÌýP, Traulsen ÌýJM. ÌýFrom consumerism to active dependence: patterns of medicines use and treatment decisions among patients with atopic dermatitis.Ìý ÌýHealth (London). 2010;14(1):91-106. doi:
54.
O’Connor ÌýC, Dhonncha ÌýEN, Murphy ÌýM. Ìý“His first word was ‘cream’:†the burden of treatment in pediatric atopic dermatitis—a mixed methods study.Ìý ÌýDermatol Ther. 2022;35(3):e15273. doi:
55.
Onumah ÌýN, Kircik ÌýL. ÌýPimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis: a pilot study on patient preference.Ìý ÌýJ Drugs Dermatol. 2013;12(10):1145-1148.
56.
Okubo ÌýY, Ho ÌýKA, Fifer ÌýS, Fujita ÌýH, Oki ÌýY, Taguchi ÌýY. ÌýPatient and physician preferences for atopic dermatitis injection treatments in Japan.Ìý ÌýJ Dermatolog Treat. 2020;31(8):821-830. doi:
57.
Paller ÌýAS, McAlister ÌýRO, Doyle ÌýJJ, Jackson ÌýA. ÌýPerceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment.Ìý ÌýClin Pediatr (Phila). 2002;41(5):323-332. doi:
58.
Powell ÌýK, Le Roux ÌýE, Banks ÌýJ, Ridd ÌýMJ. ÌýGP and parent dissonance about the assessment and treatment of childhood eczema in primary care: a qualitative study.Ìý Ìýµþ²Ñ´³ Open. 2018;8(2):e019633. doi:
59.
Retzler ÌýJ, Smith ÌýA, Reaney ÌýM, Rout ÌýR, Hudson ÌýR. ÌýProcess utilities for topical treatment in atopic dermatitis.Ìý ÌýQual Life Res. 2019;28(9):2373-2381. doi:
60.
Roh ÌýNK, Han ÌýSH, Kim ÌýMJ, Ìýet al. ÌýAwareness of atopic dermatitis and attitudes toward different types of medical institutions for its treatment among adult patients and the parents of pediatric patients: a survey of 500 participants.Ìý ÌýAnn Dermatol. 2016;28(6):725-732. doi:
61.
Santer ÌýM, Muller ÌýI, Yardley ÌýL, Lewis-Jones ÌýS, Ersser ÌýS, Little ÌýP. ÌýParents’ and carers’ views about emollients for childhood eczema: qualitative interview study.Ìý Ìýµþ²Ñ´³ Open. 2016;6(8):e011887. doi:
62.
Santer ÌýM, Burgess ÌýH, Yardley ÌýL, Ìýet al. ÌýExperiences of carers managing childhood eczema and their views on its treatment: a qualitative study.Ìý ÌýBr J Gen Pract. 2012;62(597):e261-e267. doi:
63.
Santer ÌýM, Burgess ÌýH, Yardley ÌýL, Ìýet al. ÌýManaging childhood eczema: qualitative study exploring carers’ experiences of barriers and facilitators to treatment adherence.Ìý ÌýJ Adv Nurs. 2013;69(11):2493-2501. doi:
64.
Schmitt ÌýJ, Csötönyi ÌýF, Bauer ÌýA, Meurer ÌýM. ÌýDeterminants of treatment goals and satisfaction of patients with atopic eczema.Ìý ÌýJ Dtsch Dermatol Ges. 2008;6(6):458-465. doi:
65.
Smith ÌýSD, Hong ÌýE, Fearns ÌýS, Blaszczynski ÌýA, Fischer ÌýG. ÌýCorticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups.Ìý ÌýAustralas J Dermatol. 2010;51(3):168-174. doi:
66.
Steinke ÌýS, Langenbruch ÌýA, Ständer ÌýS, Franzke ÌýN, Augustin ÌýM. ÌýTherapeutic benefits in atopic dermatitis care from the patients’ perspective: results of the German national health care study ‘Atopic Health’.Ìý Ìý¶Ù±ð°ù³¾²¹³Ù´Ç±ô´Ç²µ²â. 2014;228(4):350-359. doi:
67.
Teasdale ÌýEJ, Muller ÌýI, Santer ÌýM. ÌýCarers’ views of topical corticosteroid use in childhood eczema: a qualitative study of online discussion forums.Ìý ÌýBr J Dermatol. 2017;176(6):1500-1507. doi:
68.
Thomas ÌýC, Raibouaa ÌýA, Wollenberg ÌýA, Ìýet al. ÌýPMU105 Patient preferences for systemic atopic dermatitis treatments in the UK, France and Spain: a discrete choice experiment.Ìý ÌýValue Health. 2020;23:S621. doi:
69.
Torrelo ÌýA, Ortiz ÌýJ, Alomar ÌýA, Ros ÌýS, Prieto ÌýM, Cuervo ÌýJ. ÌýAtopic dermatitis: impact on quality of life and patients’ attitudes toward its management.Ìý ÌýEur J Dermatol. 2012;22(1):97-105. doi:
70.
Veenje ÌýS, Osinga ÌýH, Antonescu ÌýI, Bos ÌýB, de Vries ÌýTW. ÌýFocus group parental opinions regarding treatment with topical corticosteroids on children with atopic dermatitis.Ìý ÌýAllergol Immunopathol (Madr). 2019;47(2):166-171. doi:
71.
Wilson ÌýF, Harnik ÌýE, Gore ÌýC. Ìý1745 Exploring parental understanding and views on topical corticosteroids (TCS) and TCS labelling in paediatric atopic dermatitis.Ìý Ìý´¡±ô±ô±ð°ù²µ²â. 2020;75(S109):568-610.
72.
Zuberbier ÌýT, Orlow ÌýSJ, Paller ÌýAS, Ìýet al. ÌýPatient perspectives on the management of atopic dermatitis.Ìý ÌýJ Allergy Clin Immunol. 2006;118(1):226-232. doi:
73.
Zeichner ÌýJ, Feldman ÌýS, Ervin ÌýC, Crawford ÌýR, Evans ÌýE, Zielinski ÌýM. Ìý26652 Patient and caregiver perspectives on treatment attributes for atopic dermatitis.Ìý ÌýJ Am Acad Dermatol. 2021;85(3):AB111. doi:
74.
Augustin ÌýM, Langenbruch ÌýA, Blome ÌýC, Ìýet al. ÌýCharacterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation.Ìý ÌýJ Eur Acad Dermatol Venereol. 2020;34(1):142-152. doi:
75.
Xie ÌýF, Zhou ÌýT. ÌýIndustry sponsorship bias in cost effectiveness analysis: registry based analysis.Ìý Ìýµþ²Ñ´³. 2022;377:e069573. doi:
Views 3,097
Review
January 25, 2023

Values and Preferences of Patients and Caregivers Regarding Treatment of Atopic Dermatitis (Eczema): A Systematic Review

Author Affiliations
  • 1Department of Medicine, McMaster University, Hamilton, Canada
  • 2Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway
  • 3Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Canada
  • 4Department of Preventive Medicine, Faculdade de Medicina Universidade de Sao Paulo, Sao Paulo, Brazil
  • 5Faculty of Medicine, University of Ottawa, Ontario, Canada
  • 6Allergy & Asthma Network, Vienna, Virginia
  • 7Department of Pediatrics, University of Florida, Gainesville
  • 8Icahn School of Medicine at Mount Sinai, New York City, New York
  • 9Division of Allergy and Immunology, Children’s Hospital of Philadelphia, Department of Pediatrics–Perelman School of Medicine at University of Pennsylvania, Philadelphia
  • 10Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC
  • 11Children’s Hospital Los Angeles, University of Southern California, Los Angeles
  • 12Tufts University School of Medicine, Boston, Massachusetts
  • 13University of Massachusetts Chan Medical School, Worcester
  • 14Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 15School for Engineering of Matter, Transport and Energy, Arizona State University, Tempe
  • 16Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 17Toronto, Ontario
  • 18Orthopedic Neurological Rehabilitation, Northridge, California
  • 19University of Colorado School of Medicine, Aurora
  • 20Department of Family Medicine, UPMC St Margaret, Pittsburgh, Pennsylvania
  • 21Westerville, Ohio
  • 22Global Parents for Eczema Research, California
  • 23Department of Dermatology; University of Rochester Medical Center, Rochester, New York
  • 24National Jewish Health, Denver, Colorado
  • 25National Eczema Association, Novato, California
  • 26Origins Dermatology Centre, University of Saskatchewan, Regina, Saskatchewan, Canada
  • 27The Research Institute of St Joe's Hamilton, Hamilton, Canada
JAMA Dermatol. 2023;159(3):320-330. doi:10.1001/jamadermatol.2022.6045
Key Points

QuestionÌý What do patients and caregivers value when choosing treatments for atopic dermatitis?

FindingsÌý In this systematic synthesis of 62 studies including 19 442 participants, patients and caregivers preferred avoiding adverse effects and valued treatment approaches that relieve itching and burning, are minimally disruptive to daily activities, have limited visibility, and sparingly use topical corticosteroids. Some studies presented varied perspectives, and 18 were at high risk for industry sponsorship bias.

MeaningÌý In the first systematic review to address patient values and preferences in the management of atopic dermatitis to our knowledge, 6 key themes that may inform optimal clinical care, practice guidelines, and future research have been identified.

Abstract

ImportanceÌý Patient values and preferences can inform atopic dermatitis (AD) care. Systematic summaries of evidence addressing patient values and preferences have not previously been available.

ObjectiveÌý To inform American Academy of Allergy, Asthma & Immunology (AAAAI)/American College of Allergy, Asthma and Immunology (ACAAI) Joint Task Force on Practice Parameters AD guideline development, patient and caregiver values and preferences in the management of AD were systematically synthesized.

Evidence ReviewÌý Paired reviewers independently screened MEDLINE, Embase, PsycINFO, and CINAHL databases from inception until March 20, 2022, for studies of patients with AD or their caregivers, eliciting values and preferences about treatment, rated risk of bias, and extracted data. Thematic and inductive content analysis to qualitatively synthesize the findings was used. Patients, caregivers, and clinical experts provided triangulation. The GRADE-CERQual (Grading of Recommendations Assessment, Development and Evaluation–Confidence in the Evidence from Reviews of Qualitative Research) informed rating of the quality of evidence.

FindingsÌý A total of 7780 studies were identified, of which 62 proved eligible (n = 19 442; median age across studies [range], 15 years [3-44]; 59% female participants). High certainty evidence showed that patients and caregivers preferred to start with nonmedical treatments and to step up therapy with increasing AD severity. Moderate certainty evidence showed that adverse effects from treatment were a substantial concern. Low certainty evidence showed that patients and caregivers preferred odorless treatments that are not visible and have a minimal effect on daily life. Patients valued treatments capable of relieving itching and burning skin and preferred to apply topical corticosteroids sparingly. Patients valued a strong patient-clinician relationship. Some studies presented varied perspectives and 18 were at high risk for industry sponsorship bias.

Conclusions and RelevanceÌý In the first systematic review to address patient values and preferences in management of AD to our knowledge, 6 key themes that may inform optimal clinical care, practice guidelines, and future research have been identified.

×